Yesterday, ACSH s Dr. Gilbert Ross presented ACSH s position on access to reduced-risk tobacco and nicotine products at the FDA s public meeting on nicotine replacement therapies and smoking-cessation products.
The science and policy of minimising risks associated with substance use, high-risk behaviours, and public health challenges — grounded in evidence rather than stigma.
